• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Intramuscular oxytocin versus oxytocin/ergometrine versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: study protocol for a randomised controlled trial (the IMox study)
【2h】

Intramuscular oxytocin versus oxytocin/ergometrine versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: study protocol for a randomised controlled trial (the IMox study)

机译：肌内催产素与催产素/麦角新碱与卡比妥星预防阴道分娩后原发性产后出血：一项随机对照试验的研究方案（IMox研究）

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundPostpartum haemorrhage remains a major cause of maternal mortality and morbidity worldwide. Active management of the third stage of labour reduces the risk of postpartum haemorrhage. Oxytocin and oxytocin/ergometrine are commonly used in the UK, with oxytocin/ergometrine being more effective at preventing moderate, but not severe, blood loss. Many guidelines specifically recommend using oxytocin for all vaginal births, as it is associated with fewer adverse events. However, a survey conducted by the Southmead Hospital Maternity Research Team revealed that 71.4% of UK obstetric units still routinely use oxytocin/ergometrine. Carbetocin is a newer medication that may be as effective but has fewer side effects. No studies have directly compared all three medications.
机译：背景产后出血仍然是全世界孕产妇死亡和发病的主要原因。积极管理第三产程可降低产后出血的风险。催产素和催产素/麦角新碱在英国很常见，催产素/麦角新碱在预防中度（而非严重）失血方面更有效。许多指南特别建议催产素用于所有阴道分娩，因为它与较少的不良事件相关。然而，Southmead医院产妇研究小组进行的一项调查显示，英国71.4％的产科单位仍常规使用催产素/麦角新碱。 Carbetocin是一种较新的药物，可能同样有效，但副作用较少。没有研究直接比较这三种药物。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号